Ambulatory infusion device with sensor testing unit
US-9222987-B2 · Dec 29, 2015 · US
US2021121624A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2021121624-A1 |
| Application number | US-202017078816-A |
| Country | US |
| Kind code | A1 |
| Filing date | Oct 23, 2020 |
| Priority date | Oct 23, 2019 |
| Publication date | Apr 29, 2021 |
| Grant date | — |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Implantable infusion devices and methods that provide closed loop control.
Opening claim text (preview).
We claim: 1 . A method, comprising the steps of: delivering pain medication to a patient with an implantable infusion device; monitoring biometric data of the patient with a patient monitor; determining, with the implantable infusion device, whether or not the monitored biometric data is indicative of an opioid overdose; and immediately ending delivery of the pain medication with the implantable infusion device in response to a determination by the implantable infusion device that the monitored biometric data is indicative of an opioid overdose. 2 . A method as claimed in claim 1 , further comprising the step of: transmitting an opioid overdose alert in response to a determination by the implantable infusion device that the monitored biometric data is indicative of an opioid overdose. 3 . A method as claimed in claim 1 , wherein the monitored biometric data comprises one or more of respiration rate, blood oxygen saturation (SpO2), blood pressure, body temperature, heart rate, heart rate variability, accelerometer data, skin conductance, EMG, EEG and facial expressions. 4 . A method as claimed in claim 1 , wherein the implantable infusion device includes housing, a reservoir within the housing, and a fluid transfer device within the housing; and monitoring biometric data comprises monitoring biometric with a sensor that is within the housing. 5 . A method as claimed in claim 1 , wherein monitoring biometric data comprises monitoring biometric data with a body worn sensor; and the method further comprises wirelessly transmitting the monitored biometric data from the body worn sensor to the implantable infusion device. 6 . A method as claimed in claim 1 , further comprising the steps of determining, with the implantable infusion device, whether or not the monitored biometric data is indicative of pain above a predetermined threshold; and increasing delivery of the pain medication with the implantable infusion device in response to a determination by the implantable infusion device that the monitored biometric data is indicative of pain above the predetermined threshold. 7 . An implantable infusion device, comprising: an outlet port configured to be secured to a catheter; a reservoir configured to store an infusible substance; a fluid transfer device, operably connected to the reservoir and outlet port, configured to transfer the infusible substance from the reservoir to the outlet when actuated; and a controller, operably connected to the fluid transfer device, configured to actuate the fluid transfer device in accordance with a stored delivery profile, to receive monitored biometric data, to determine whether or not the monitored biometric data is indicative of an opioid overdose, and to immediately end actuation of the fluid transfer device in response to a determination by the controller that the monitored biometric data is indicative of an opioid overdose. 8 . An implantable infusion device as claimed in claim 7 , further comprising: a wireless communication device operably connected to the controller; wherein the controller is configured to transmit an opioid overdose alert by way of the wireless communication device in response to a determination that the monitored biometric data is indicative of an opioid overdose. 9 . An implantable infusion device as claimed in claim 7 , wherein the monitored biometric data comprises one or more of respiration rate, blood oxygen saturation (SpO2), blood pressure, body temperature, heart rate, heart rate variability, accelerometer data, skin conductance, EMG, EEG and facial expressions. 10 . An implantable infusion device as claimed in claim 7 , further comprising; a housing in which the reservoir and fluid transfer device are located; and a sensor configured to monitor biometric data located within the housing and operably connected to the controller. 11 . An implantable infusion device as claimed in claim 7 , further comprising: a wireless communication device operably connected to the controller; wherein the controller is configured to receive the biometric data by way of the wireless communication device. 12 . An implantable infusion device as claimed in claim 7 , wherein the controller is configured to determine whether or not the monitored biometric data is indicative of pain above a predetermined level and to increase actuation of the fluid transfer device in response to a determination by the controller that the monitored biometric data is indicative of pain above the predetermined level. 13 . A method, comprising the steps of: delivering pain medication to a patient with an implantable infusion device; monitoring biometric data of the patient with a patient monitor; determining, with the implantable infusion device, whether or not the monitored biometric data is indicative of pain above a predetermined threshold; and increasing delivery of the pain medication with the implantable infusion device in response to a determination by the implantable infusion device that the monitored biometric data is indicative of pain above the predetermined threshold. 14 . A method as claimed in claim 13 , wherein the monitored biometric data comprises one or more of nerve activity, muscle activity, chemical signals, respiration rate, blood pressure, body temperature, heart rate, and heart rate variability. 15 . A method as claimed in claim 13 , wherein the implantable infusion device includes housing, a reservoir within the housing, and a fluid transfer device within the housing; and monitoring biometric data comprises monitoring biometric with a sensor that is within the housing. 16 . A method as claimed in claim 13 , wherein monitoring biometric data comprises monitoring biometric data with a body worn sensor; and the method further comprises wirelessly transmitting the monitored biometric data from the body worn sensor to the implantable infusion device. 17 . A method as claimed in claim 13 , wherein monitoring biometric data comprises monitoring biometric data with a sensor on a catheter. 18 . A method as claimed in claim 13 , further comprising the steps of determining, with the implantable infusion device, whether or not the monitored biometric data is indicative of an opioid overdose; and immediately ending delivery of the pain medication with the implantable infusion device in response to a determination by the implantable infusion device that the monitored biometric data is indicative of an opioid overdose. 19 . An implantable infusion device, comprising: an outlet port configured to be secured to a catheter; a reservoir configured to store an infusible substance; a fluid transfer device, operably connected to the reservoir and outlet port, configured to transfer the infusible substance from the reservoir to the outlet when actuated; and a controller, operably connected to the fluid transfer device, configured to actuate the fluid transfer device in accordance with a stored delivery profile, to receive monitored biometric data, to determine whether or not the monitored biometric data is indicative of pain above a predetermined level, and to increase delivery of the infusible substance in response to a determination by the controller that the monitored biometric data is indicative of pain above the predetermined level. 20 . An implantable infusion device as claimed in claim 19 , wherein the monitored biometric data comprises one or more of nerve activity, muscle activity,
specially adapted for implantation · CPC title
Touch-screens; Virtual keyboard or keypads; Virtual buttons; Soft keys; Mouse touches · CPC title
Using a biosensor · CPC title
remote, e.g. between patient's home and doctor's office · CPC title
with alarm · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.